A randomized comparative study of prednimustine and doxorubicin in patients with metastatic breast cancer.
A clinical protocol outline of a study randomizing prednimustine v doxorubicin in patients with metastatic breast cancer is presented. The study has just been initiated, and no results are available at the present time. Unique features of this clinical trial are discussed, including the correlation of objective parameters of tumor response with symptomatic improvement as measured by quality of life, performance status, and pain indices as well as alterations in body weight.